Nabriva Therapeutics plc
NBRVF
$0.0001
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -55.05M | -54.07M | -57.19M | -47.47M | -46.61M |
| Total Depreciation and Amortization | 101.00K | 160.00K | 217.00K | 278.00K | 323.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.25M | 6.62M | 6.52M | 3.27M | 3.48M |
| Change in Net Operating Assets | 27.79M | 20.82M | 13.73M | 2.72M | -5.46M |
| Cash from Operations | -12.91M | -26.46M | -36.71M | -41.20M | -48.27M |
| Capital Expenditure | -115.00K | -179.00K | -211.00K | -210.00K | -106.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -49.00K | -51.00K | -52.00K | -58.00K | -58.00K |
| Cash from Investing | -164.00K | -230.00K | -263.00K | -268.00K | -164.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.83M | -7.77M | -2.92M | -1.92M | -949.00K |
| Issuance of Common Stock | 2.54M | 3.35M | 5.58M | 7.65M | 9.80M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -122.00K | -766.00K | -811.00K | -1.08M | -1.24M |
| Cash from Financing | -4.40M | -5.20M | 1.85M | 4.65M | 7.61M |
| Foreign Exchange rate Adjustments | -432.00K | -153.00K | -174.00K | -582.00K | -339.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.91M | -32.04M | -35.30M | -37.41M | -41.16M |